Apoha is a London- and San Francisco-based deep-tech company building what it calls the next fundamental data class of molecular science. Where genomics digitised the sequence of biology and structural biology digitised the shape of molecules, Apoha aims to digitise behaviour — what matter actually does under stress, excitation, and real-world conditions. The company argues that today's AI models for drug discovery, food science, and materials are fundamentally data-starved because conventional assays measure one property at a time, slowly and expensively.
The company's foundational technology is named Liquid State Intelligence, and its first commercial readout is VIBE (Variations in Inter-facial Behaviour Under Excitation). The platform takes a quantity of material small enough to sit on a pinhead, suspends it in liquid, applies a programmed sequence of perturbations, and records the wave patterns the molecule throws off. Those waveforms resolve into more than 1,000 measured descriptors of behaviour in a single reading, a dramatic leap in information density over single-property assays.
Apoha was co-founded by an Oxford physicist and a former Goldman Sachs quant, who pair a hardware-driven measurement layer with machine learning that maps waveforms to functional properties. The data feeds AI models that can rank and design candidates for antibodies, small molecules, food ingredients, paints, and other substances. One early result: the platform is used by Boehringer Ingelheim to identify high-risk antibody candidates with greater than 90% precision from just 8 micrograms of material.
The company emerged from stealth on June 3, 2026 with $36 million in venture funding, a round led by European VC firm Singular with participation from Draper Associates and continued backing from seed investors Redalpine, Seedcamp, Wilbe, and Nucleus. It also holds a grant from Innovate UK. The capital funds scaling of the VIBE platform and expansion of partnerships across pharma, biotech, and food and beverage companies.
Apoha positions itself less as a single-vertical biotech and more as a horizontal data-layer company — an instrument plus model platform that any organisation working with matter could plug into, much as genomic sequencing became infrastructure for an entire industry.